StevenQuay @atossainc discusses why the company’s experimental breast therapy is being developed to treat two rare diseases, the studies needed to test them, and the business decisions involved in expanding into rare disease. @GlobalGenes#RARECast https://t.co/wRDaiLec1q
@nuvationbioinc CEO David Hung discusses Ibtrozi for ROS1-positive lung cancer and his plans to build a broader oncology business.
https://t.co/zhgaD2nVaT
@nuvationbioinc CEO David Hung discusses Ibtrozi for ROS1-positive lung cancer and his plans to build a broader oncology business.
https://t.co/zhgaD2nnll
@ProtagonistTx CEO Dinesh Patel discusses the company's peptide therapy for the rare blood disorder polycythemia vera its potential to reduce the burden blood withdrawals for people with the condition. @globalgenes#RARECast
https://t.co/vURHyFGXaP
Can altering RNA processing reach undruggable cancer targets? Remix Therapeutics CEO Peter Smith on the company’s experimental oral drugs that hit MYB, an elusive cancer target. https://t.co/9rQsqToyHw
Carol Roberts @PBCers discusses her experience with the rare autoimmune condition primary biliary cholangitis, what a recent patient survey reveals about its day-to-day toll, and the evolving treatment landscape. @GlobalGenes#RARECast
https://t.co/4A4RHBlU4l
Nima Farzan @latigobio discusses the science behind the company’s approach to treating pain, what the data suggest about the potential to reduce opioid use after surgery, and what clinicians and insurers will need to see beyond regulatory approval.
https://t.co/oOT46PohAy
Susan Busch @YearningNormal discusses her book Yearning for Normal, her son’s life with 22q11.2 deletion syndrome and the love and self-doubt of caregiving. @GlobalGenes#RARECast https://t.co/ewgwrsZ1VQ
@johnbstanford of the policy organization @incub8coalition discusses biotech investors’ growing focus on policy risks, from drug pricing to competition with China.
https://t.co/1hGlHmhfx2
@thisislukasl@ProbGenetic discusses the company’s direct-to-patient data platform, its ARPA-H-supported Project Rosetta, and how richer patient data could shorten the diagnostic journey and lead to new treatments. @GlobalGenes#RARECast
https://t.co/KZ4ipt6vYH
Targeting metastatic breast cancer: @BriaCell CEO William Williams discusses its experimental, phase 3, off-the-shelf cell therapy.
https://t.co/YBLKXqbhGR
Ankit Jain, CEO of Infinitus, discusses how his daughter’s rare disease exposed the obstacles families face, how the company’s AI agents work to reduce delays, and where human judgment and connection must remain central to care. @GlobalGenes#RARECast
https://t.co/x3wutPTkVn
@Harithr@FractylHealth on its shift from type 2 diabetes to sustaining weight loss after patients stop GLP-1 medicines, the biology behind its approach, and how to turn the promise of a metabolic reset into a treatment.
https://t.co/Ls7XiODYm6
Arun Swaminathan @CoyaTx discusses how dysfunctional regulatory T cells contribute to neuroinflammation and neuronal damage in ALS, why the company is targeting them as a driver of disease progression, and the case for its dual immunomodulatory approach.
https://t.co/eU4hlpfgNB
Geoff McDonough @RezeraInc discusses inflammation in heart disease, the company’s phase 3 trial of ruvonoflast in peripheral artery disease, and its next-generation, brain-penetrant NLRP3 inhibitor in development for neuroinflammatory conditions.
https://t.co/KERWpgshZr
How can patient advocates and industry collaborate more effectively on drug development? Watch our panel from the @GlobalGenes Rare Drug Development Symposium @wendy_erler, Michelle Davis @ifopa, @TaiPasquini
https://t.co/rJrZlyaHg0
Patient advocate Monica Dubeau of https://t.co/w61Vel13TU discusses fragmented care, diagnostic delay, and what must change for people with rare diseases. @GlobalGenes#RARECast https://t.co/8OMpflO3LZ
Ryan Beal @DyveBio discusses why acidity is an overlooked but foundational target in oncology, how its delivery technology may overcome the limitations of oral bicarbonate dosing, and indications beyond cancer that the company is pursuing.
https://t.co/v3xecInGMX